期刊
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
卷 8, 期 6, 页码 665-676出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.2012.680885
关键词
anticancer; antiretroviral; antiviral; mitochondria; nucleoside analogs; nucleoside transporters
资金
- National Institute of Drug Abuse/National Institutes of Health/United States Department of Health and Human Services [1R01DA030996]
Introduction: Two families of nucleoside analogs have been developed to treat viral infections and cancer, but these compounds can cause tissue- and cell-specific toxicity related to their uptake and subcellular activity, which are dictated by host enzymes and transporters. Cellular uptake of these compounds requires nucleoside transporters that share functional similarities but differ in substrate specificity. Tissue-specific cellular expression of these transporters enables nucleoside analogs to produce their tissue- specific toxic effects, a limiting factor in the treatment of retroviruses and cancer. Areas covered: This review discusses the families of nucleoside transporters and how they mediate cellular uptake of nucleoside analogs. Specific focus is placed on examples of known cases of transporter-mediated cellular toxicity and classification of the toxicities resulting. Efflux transporters are also explored as a contributor to analog toxicity and cell-specific effects. Expert opinion: Efforts to modulate transporter uptake/clearance remain long-term goals of oncologists and virologists. Accordingly, subcellular approaches that either increase or decrease intracellular nucleoside analog concentrations are eagerly sought and include transporter inhibitors and targeting transporter expression. However, additional understanding of nucleoside transporter kinetics, tissue expression and genetic polymorphisms is required to design better molecules and better therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据